Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
08 mai 2024 17h35 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
06 mai 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
22 avr. 2024 07h00 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
09 avr. 2024 07h00 HE
|
Plus Therapeutics Inc.
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’...
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
27 mars 2024 08h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25 mars 2024 08h00 HE
|
Plus Therapeutics Inc.
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an...
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
11 mars 2024 07h00 HE
|
Plus Therapeutics Inc.
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) --...
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
05 mars 2024 16h05 HE
|
Plus Therapeutics Inc.
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
27 févr. 2024 08h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Updates Financial and Cash Guidance for 2024
18 déc. 2023 07h00 HE
|
Plus Therapeutics Inc.
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M ...